Nevertheless, the relevant finding of the present assay was that irrespective of possible changes in receptors’ expression, a higher interaction between D2R and A2AR would occur, which might be considered both as a pathological fingerprint and a pharmacological target in PD. Here, ADORA2A is linked to Parkinson disease.